Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.

Article  PubMed  PubMed Central  Google Scholar 

Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6:e8.

Article  PubMed  PubMed Central  Google Scholar 

Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15:4263–9.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, et al. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig. 2017;4:48.

Article  PubMed  PubMed Central  Google Scholar 

Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–42.

Article  PubMed  Google Scholar 

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96:1993–2003.

Article  PubMed  PubMed Central  Google Scholar 

Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:612880.

Article  PubMed  PubMed Central  Google Scholar 

Li S, Li N, Chen Y, Zheng Z, Guo Y. FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis. Front Oncol. 2023;13:1086846.

Article  PubMed  PubMed Central  Google Scholar 

Tamburini J, Mouche S, Larrue C, Duployez N, Bidet A, Salotti A, et al. Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia. Blood Adv. 2023;7:7576–80.

Article  PubMed  PubMed Central  Google Scholar 

Jensen CE, Montgomery ND, Galeotti J, Foster MC, Zeidner JF. Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia. J Cell Mol Med. 2022;26:6079–82.

Article  PubMed  PubMed Central  Google Scholar 

Stasik S, Kramer M, Zukunft S, Röllig C, Baldus CD, Platzbecker U, et al. Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD. Front Oncol. 2022;12:862991.

Article  PubMed  PubMed Central  Google Scholar 

Ge S-S, Qiu Q-C, Dai H-P, Shen X-D, Wu T-M, Du J-H, et al. Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. Br J Haematol. 2023;202:539–49.

Article  PubMed  Google Scholar 

Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol. 2004;124:481–4.

Article  PubMed  Google Scholar 

Syampurnawati M, Tatsumi E, Furuta K, Hayashi Y. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene. Leuk Res. 2007;31:877.

Article  PubMed  Google Scholar 

Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006;107:3700–7.

Article  PubMed  Google Scholar 

Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12:501–13.

Article  PubMed  Google Scholar 

Young DJ, Nguyen B, Zhu R, Seo J, Li L, Levis MJ, et al. Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. Blood Adv. 2021;5:2285–93.

Article  PubMed  PubMed Central  Google Scholar 

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl J Med. 1994;331:896–903.

Article  PubMed  Google Scholar 

Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997;89:780–8.

Article  PubMed  Google Scholar 

Schiffer CA, Davis RB, Schulman P, Cooper B, Coyle T, Lee E, et al. Intensive post remission therapy of acute myeloid leukemia (AML) with cytoxan/etoposide (CY/VP16) and diazaquone/mitoxantrone (AZQ/MITO). Blood. 1991;78:460. (abstract 1829).

Google Scholar 

Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol. 2004;22:4290–301.

Article  PubMed  Google Scholar 

Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005;105:3420–7.

Article  PubMed  PubMed Central  Google Scholar 

Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413–21.

Article  PubMed  PubMed Central  Google Scholar 

Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503). Leukemia. 2017;31:34–9.

Article  PubMed  Google Scholar 

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl J Med. 2017;377:454–64.

Article  PubMed  PubMed Central  Google Scholar 

Eisfeld AK, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211–8.

Article  PubMed  PubMed Central  Google Scholar 

Kroll KW, Eisfeld AK, Lozanski G, Bloomfield CD, Byrd JC, Blachly JS. MuCor: mutation aggregation and correlation. Bioinformatics. 2016;32:1557–8.

Article  PubMed  PubMed Central  Google Scholar 

Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, et al. Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front Oncol. 2019;9:851.

Article  PubMed  PubMed Central  Google Scholar 

Baker SD, Zimmerman EI, Wang Y-D, Orwick S, Zatechka DS, Buaboonnam J, et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD–positive acute myeloid leukemia. Clin Cancer Res. 2013;19:5758–68.

Article  PubMed  Google Scholar 

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia. Blood. 2013;122:3607–15.

Article  PubMed  PubMed Central  Google Scholar 

Jarusiewicz JA, Jeon JY, Connelly MC, Chen Y, Yang L, Baker SD, et al. Discovery of a diaminopyrimidine FLT3 inhibitor active against acute myeloid leukemia. ACS Omega. 2017;2:1985–2009.

Article  PubMed  PubMed Central  Google Scholar 

Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, et al. The Structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13:169–178.

Article